News

 

 

AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that a case study highlighting the...

Read more about AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference

AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that the U.S.

Read more about AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal

AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that its board of directors has...

Read more about AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split

Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals

PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Apr. 13, 2017-- Link here

Read more about Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals

AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that data from its investigational bacteriophage programs,...

Read more about AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences

FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell®

Valencia, CA, Perth, Australia and London, United Kingdom, 7 April 2017 – link here

Read more about FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell®

Adherium chosen as Finalist in NZ Hi-Tech Awards

Entries this year came from as far afield as Kaitaia and Invercargill which have resulted in a record number of entries being received, up 30% on last year.

Read more about Adherium chosen as Finalist in NZ Hi-Tech Awards

AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the quarter and...

Read more about AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights

Avita Medical to Present at Needham Healthcare Conference

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 23 March 2017 — Link here

Read more about Avita Medical to Present at Needham Healthcare Conference

Come meet Adherium at RDD Europe 2017

Garth Sutherland, Adherium CEO & Founder, selected as a Speaker and author at the upcoming meeting, RDD Europe 2017 to be held April 25-28, 2017, at Palais des Congres d'Antibes, Nice (Antibes), France.

Read more about Come meet Adherium at RDD Europe 2017

1 2 3 4 5 ... 25